Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling αVβ3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor

Molecular Biology of the Cell

Volumn 20, Issue 3, 2009, Pages 745-756

  Schiller, Herbert B ^a   Szekeres, Andreas ^a   Binder, Bernd R ^a   Stockinger, Hannes ^a   Leksa, Vladimir ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; MANNOSE 6 PHOSPHATE; PLASMINOGEN; SOMATOMEDIN B RECEPTOR; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN; VITRONECTIN RECEPTOR; PLASMIN;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; LIGAND BINDING; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RNA INTERFERENCE; ANIMAL; CANCER INVASION; CELL LINE; CELL MEMBRANE; CELL MOTION; ENDOCYTOSIS; METABOLISM; MOUSE; PROTEIN BINDING;

ANIMALS; CELL ADHESION; CELL LINE; CELL MEMBRANE; CELL MOVEMENT; ENDOCYTOSIS; HUMANS; INTEGRIN ALPHAVBETA3; MICE; NEOPLASM INVASIVENESS; PLASMIN; PLASMINOGEN; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, IGF TYPE 2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA INTERFERENCE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 64049103845     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E08-06-0569     Document Type: Article

References (57)

1. Arap, W., and Huang, H. J. (1999). Expression of Integrin Transcripts in Human Cancer Cells, Totowa, NJ: Humana Press.
2. Beaufort, N., Leduc, D., Rousselle, J. C., Namane, A., Chignard, M., and Pidard, D. (2004). Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett. 574, 89-94.
3. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dano, K. (1991). The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 266, 7842-7847.
4. Bernstein, A. M., Twining, S. S., Warejcka, D. J., Tall, E., and Masur, S. K. (2007). Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol. Biol. Cell 18, 2716-2727.
5. Berthe, M. L., Esslimani Sahla, M., Roger, P., Gleizes, M., Lemamy, G. J., Brouillet, J. P., and Rochefort, H. (2003). Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas. Eur. J. Cancer 39, 635-642.
6. Chen, J., Baskerville, C., Han, Q., Pan, Z. K., and Huang, S. (2001). α(v) Integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J. Biol. Chem. 276, 47901-47905.
7. Cunningham, O., Andolfo, A., Santovito, M. L., Iuzzolino, L., Blasi, F., and Sidenius, N. (2003). Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 22, 5994-6003.
8. Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Romer, J. (2005). Plasminogen activation and cancer. Thromb. Hae-most. 93, 676-681.
9. Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., and Sarkar, F. H. (2008). Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 34, 122-136.
10. Dennis, P. A., and Rifkin, D. B. (1991). Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA 88, 580-584.
11. Ellis, V., Whawell, S. A., Werner, F., and Deadman, J. J. (1999). Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen. Biochemistry 38, 651-659.
12. Felding-Habermann, B., Fransvea, E., O'Toole, T. E., Manzuk, L., Faha, B., and Hensler, M. (2002). Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 19, 427-436.
13. Felding-Habermann, B. et al. (2001). Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 98, 1853-1858.
14. Ghosh, P., Dahms, N. M., and Kornfeld, S. (2003). Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202-212.
15. Godar, S., Horejsi, V., Weidle, U. H., Binder, B. R., Hansmann, C., and Stockinger, H. (1999). M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur. J. Immunol. 29, 1004-1013.
16. Gruber, F. et al. (2003). Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood 101, 3042-3048.
17. Guvakova, M. A. (2007). Insulin-like growth factors control cell migration in health and disease. Int. J. Biochem. Cell Biol. 39, 890-909.
18. Han, H. J., Russo, J., Kohwi, Y., and Kohwi-Shigematsu, T. (2008). SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452, 187-193.
19. Hebert, E. (2006). Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci. Rep. 26, 7-17.
20. Hoyer-Hansen, G., Behrendt, N., Ploug, M., Dano, K., and Preissner, K. T. (1997). The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420, 79-85.
21. Hoyer-Hansen, G., Ronne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Dano, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267, 18224-18229.
22. Kang, J. X., Li, Y., and Leaf, A. (1997). Mannose-6-phosphate/insulin- like growth factor-II receptor is a receptor for retinoic acid. Proc. Natl. Acad. Sci. USA 94, 13671-13676.
23. Kasper, D., Dittmer, F., von Figura, K., and Pohlmann, R. (1996). Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. J. Cell Biol. 134, 615-623.
24. Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Gunzler, W. A., Janicke, F., and Graeff, H. (1991). Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem. 266, 5147-5152.
25. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P. C., and Binder, B. R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567.
26. Kreiling, J. L., Byrd, J. C., Deisz, R. J., Mizukami, I. F., Todd, R. F., 3rd, and MacDonald, R. G. (2003). Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR. J. Biol. Chem. 278, 20628-20637.
27. Lee, J. S., Weiss, J., Martin, J. L., and Scott, C. D. (2003). Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer 107, 564-570.
28. Leivonen, S. K., and Kahari, V. M. (2007). Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 121, 2119-2124.
29. Leksa, V., Godar, S., Cebecauer, M., Hilgert, I., Breuss, J., Weidle, U. H., Horejsi, V., Binder, B. R., and Stockinger, H. (2002). The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J. Biol. Chem. 277, 40575-40582.
30. Leksa, V. et al. (2005). TGF-{beta}-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J. Cell Sci. 118, 4577-4586.
31. Lorenzo, K., Ton, P., Clark, J. L., Coulibaly, S., and Mach, L. (2000). Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin-like growth factor II receptor. Cancer Res. 60, 4070 -4076.
32. Lutz, V., Reuning, U., Kruger, A., Luther, T., von Steinburg, S. P., Graeff, H., Schmitt, M., Wilhelm, O. G., and Magdolen, V. (2001). High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol. Chem. 382, 789-798.
33. MacDonald, R. G., and Byrd, J. C. (2003). The insulin-like growth factor II/mannose 6-phosphate receptor: implications for IGF action in breast cancer. Breast Dis. 17, 61-72.
34. Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O., and Sidenius, N. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 177, 927-939.
35. Madsen, C. D., and Sidenius, N. (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol. 87, 617-629.
36. Mazar, A. P., Henkin, J., and Goldfarb, R. H. (1999). The urokinase plasmin-ogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3, 15-32.
37. Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L., and Blasi, F. (2006). An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17, 367-378.
38. Montuori, N., Carriero, M. V., Salzano, S., Rossi, G., and Ragno, P. (2002). The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 277, 46932-46939.
39. Montuori, N., Visconte, V., Rossi, G., and Ragno, P. (2005). Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93, 192-198.
40. Motyka, B. et al. (2000). Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103, 491-500.
41. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
42. Nykjaer, A., Christensen, E. I., Vorum, H., Hager, H., Petersen, C. M., Roigaard, H., Min, H. Y., Vilhardt, F., Moller, L. B., Kornfeld, S., and Gliemann, J. (1998). Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol. 141, 815-828.
43. Nykjaer, A., Conese, M., Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997). Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16, 2610-2620.
44. Pilch, J., Habermann, R., and Felding-Habermann, B. (2002). Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J. Biol. Chem. 277, 21930-21938.
45. Prager, G. W., Breuss, J. M., Steurer, S., Olcaydu, D., Mihaly, J., Brunner, P. M., Stockinger, H., and Binder, B. R. (2004). Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res. 94, 1562-1570.
46. Ragno, P. (2006). The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol. Life Sci. 63, 1028-1037.
47. Ragno, P., Montuori, N., Covelli, B., Hoyer-Hansen, G., and Rossi, G. (1998). Differential expression of a truncated form of the urokinase-type plasmino-gen-activator receptor in normal and tumor thyroid cells. Cancer Res. 58, 1315-1319.
48. Ravanko, K., Jarvinen, K., Helin, J., Kalkkinen, N., and Holtta, E. (2004). Cysteine cathepsins are central contributors of invasion by cultured adeno-sylmethionine decarboxylase-transformed rodent fibroblasts. Cancer Res. 64, 8831-8838.
49. Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359-1364.
50. Rolli, M., Fransvea, E., Pilch, J., Saven, A., and Felding-Habermann, B. (2003). Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 9482-9487.
51. Samani, A. A., Yakar, S., LeRoith, D., and Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. En-docr. Rev. 28, 20-47.
52. Scott, C. D., and Firth, S. M. (2004). The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm. Metab. Res. 36, 261271.
53. Smith, H. W., Marra, P., and Marshall, C. J. (2008). uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J. Cell Biol. 182, 777-790.
54. Tarui, T. et al. (2006). Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost. 95, 524-534.
55. Tarui, T., Majumdar, M., Miles, L. A., Ruf, W., and Takada, Y. (2002). Plasmin-induced migration of endothelial cells. A potential target for the anti-angio-genic action of angiostatin. J. Biol. Chem. 277, 33564-33570.
56. van den Hoff, M. J., Moorman, A. F., and Lamers, W. H. (1992). Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res. 20, 2902.
57. Wei, C. et al. (2008). Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63.